Literature DB >> 18171252

What is the "therapeutic range" for voriconazole?

Russell E Lewis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18171252     DOI： 10.1086/524670

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

2.  Concentrations of voriconazole in healthy and inflamed lung in rats.

Authors:  Christian Joukhadar; Christiane Thallinger; Wolfgang Pöppl; Florian Kovar; Karl H Konz; Samir M Joukhadar; Friederike Traunmüller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

3.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

4.  Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.

Authors:  I Fan Kuo; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-11

5.  Ventricular Tachycardia: A Rare Side Effect of Voriconazole.

Authors:  Pooja Dewan; Sunil Gomber; Vanny Arora
Journal:  Indian J Pediatr       Date:  2016-08-24       Impact factor: 1.967

6.  Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.

Authors:  Jiun-Ling Wang; Chia-Hsuin Chang; Yinong Young-Xu; K Arnold Chan
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 7.  Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review.

Authors:  Perrine Parize; Marie-Olivia Chandesris; Fanny Lanternier; Sylvain Poirée; Jean-Paul Viard; Boris Bienvenu; Michaël Mimoun; Frédéric Méchai; Marie-France Mamzer; Philippe Herman; Marie-Elisabeth Bougnoux; Marc Lecuit; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

Review 8.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705

9.  A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.

Authors:  Shinsuke Takagi; Hideki Araoka; Naoyuki Uchida; Yumiko Uchida; Daisuke Kaji; Hikari Ota; Aya Nishida; Kazuya Ishiwata; Masanori Tsuji; Hisashi Yamamoto; Tadaaki Ito; Naofumi Matsuno; Go Yamamoto; Yuki Asano-Mori; Masahiro Hayashi; Koji Izutsu; Kazuhiro Masuoka; Atsushi Wake; Shigeyoshi Makino; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Int J Hematol       Date:  2014-03-25       Impact factor: 2.490

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.